Pharsight

Epiduo patents expiration

EPIDUO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8936800 GALDERMA LABS LP Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
Dec, 2022

(1 year, 4 months ago)

US8809305 GALDERMA LABS LP Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris
Dec, 2022

(1 year, 4 months ago)

US8105618 GALDERMA LABS LP Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide
Dec, 2022

(1 year, 4 months ago)

US8241649 GALDERMA LABS LP Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide
Dec, 2022

(1 year, 4 months ago)

US7964202 GALDERMA LABS LP Method for treatment of common acne
Sep, 2024

(4 months from now)

US7820186 GALDERMA LABS LP Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
Nov, 2025

(1 year, 6 months from now)

US8445543 GALDERMA LABS LP Combinations of adapalene and benzoyl peroxide for treating acne lesions
Jul, 2027

(3 years from now)

US8129362 GALDERMA LABS LP Combination/association of adapalene and benzoyl peroxide for treating acne lesions
Jul, 2027

(3 years from now)

US8080537 GALDERMA LABS LP Combinations of adapalene and benzoyl peroxide for treating acne lesions
Jul, 2027

(3 years from now)

US8071644 GALDERMA LABS LP Combinations of adapalene and benzoyl peroxide for treating acne lesions
Jul, 2027

(3 years from now)

Epiduo is owned by Galderma Labs Lp.

Epiduo contains Adapalene; Benzoyl Peroxide.

Epiduo has a total of 10 drug patents out of which 4 drug patents have expired.

Expired drug patents of Epiduo are:

  • US8936800
  • US8809305
  • US8105618
  • US8241649

Epiduo was authorised for market use on 08 December, 2008.

Epiduo is available in gel;topical dosage forms.

Epiduo can be used as treatment of acne.

The generics of Epiduo are possible to be released after 18 July, 2027.

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Dec 08, 2011
New Patient Population(NPP) Feb 01, 2016

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Market Authorisation Date: 08 December, 2008

Treatment: Treatment of acne

Dosage: GEL;TOPICAL

How can I launch a generic of EPIDUO before it's drug patent expiration?
More Information on Dosage

EPIDUO family patents

Family Patents